Methimazole 5 mg Tablet, 500-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Thyroid Hormone Synthesis Inhibitor class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Methimazole tells your thyroid gland to stop making so much thyroid hormone. When your thyroid is overactive — like in Graves' disease — it pumps out too much hormone and speeds ev...
- What exactly is methimazole supposed to do for me?
- Usually you'll take it in three separate doses spaced about 8 hours apart throughout the day — so think morning, afternoon, and evening. Your prescriber sets the exact dose based o...
- How do I take it — do I take it all at once?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Methimazole — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.071 | $35.35 / 500 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2101 | $105.05 / 500 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.1781 | $89.05 / 500 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Methimazole 5 mg 00832-6072-11 | Upsher-Smith | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 11788-0011-01 | AiPing | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 23155-0070-01 | Heritage | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 33342-0335-11 | Macleods | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 50268-0495-15 | AvPAK | 50 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 60687-0669-01 | American | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mgthis 64380-0212-02 | Strides | 500 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 64980-0264-01 | Rising | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 69452-0328-20 | Bionpharma | 100 tablets | $0.071 | AB | Availability likely | — |
| methimazole 5 mg 72578-0212-01 | Viona | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 72603-0315-01 | NORTHSTAR | 100 tablets | $0.071 | AB | Availability likely | — |
| Methimazole 5 mg 50090-6536-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 60429-0380-01 | Golden | 100 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 62135-0205-01 | Chartwell | 100 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 63629-8347-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 63629-9249-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 63629-9250-01 | Bryant | 500 tablets | — | AB | FDA listed | — |
| methimazole 5 mg 67046-1651-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 68788-8226-03 | Preferred | 30 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 68788-8883-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 70518-1506-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 71335-2881-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 71335-3026-01 | Bryant | 500 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 72162-1802-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Methimazole 5 mg 73190-0084-01 | AvKARE | 100 tablets | — | AB | FDA listed | — |
| methimazole 5 mg 76483-0082-00 | SQUARE | 100 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 64380-0212-01 | 100 TABLET in 1 BOTTLE (64380-212-01) | $0.0707 / ea | $7.07 | 2022-03-14 | Active |
| 64380-0212-02 You're viewing this | 500 TABLET in 1 BOTTLE (64380-212-02) | $0.0707 / ea | $35.37 | 2022-03-14 | Active |
| 64380-0212-03 | 1000 TABLET in 1 BOTTLE (64380-212-03) | — | — | 2024-02-28 | Active |
You're viewing one of 3 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0707 NADAC).
Pack size FAQ
What quantity is in NDC 64380-0212-02?
What is the difference between NDC 64380-0212-02 and NDC 64380-0212-01?
What NDC number is used to bill for this package of Methimazole 5 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Methimazole tablets are indicated: In patients with Graves' disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option. To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Methimazole tablets are administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals. Adult - The initial daily dosage is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8-hour intervals.
The maintenance dosage is 5 to 15 mg daily. Pediatric - Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.
⛔ Contraindications ▾
CONTRAINDICATIONS Methimazole tablets are contraindicated in the presence of hypersensitivity to the drug or any of the other product components.
⚠️ Warnings ▾
WARNINGS First Trimester Use of Methimazole and Congenital Malformations Methimazole crosses the placental membranes and can cause fetal harm, when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received methimazole tablets in the first trimester of pregnancy.
If methimazole tablets are used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. Because of the risk for congenital malformations associated with use of methimazole tablets in the first trimester of pregnancy, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism. If methimazole tablets are used, the lowest possible dose to control the maternal disease should be given.
Agranulocytosis Agranulocytosis is potentially a life-threatening adverse reaction of methimazole therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur.
The drug should be discontinued in the presence of agranulocytosis or aplastic anemia (pancytopenia), and the patient's bone marrow indices should be monitored. Liver Toxicity Although there have been reports of hepatotoxicity (including acute liver failure) associated with methimazole, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction (anorexia, pruritis, right upper quadrant pain, etc.) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST).
Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal. Hypothyroidism Methimazole can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal goiter and cretinism when administered to a pregnant woman.
For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy (see PRECAUTIONS, Pregnancy). Vasculitis Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy. These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary hemorrhage, CNS vasculitis, and neuropathy.
Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis. In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. If vasculitis is suspected, discontinue therapy and initiate appropriate intervention.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely. There have been postmarketing case reports of acute pancreatitis.
There are reports of a vasculitis, often associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications (see WARNINGS). Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy. To report SUSPECTED ADVERSE REACTIONS, contact Strides Pharma Inc. at 1-877-244-9825 or go to www.strides.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. ß-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid. Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.
Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.
🤰 Pregnancy ▾
Pregnancy See WARNINGS If methimazole tablets are used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. In pregnant women with untreated or inadequately treated Graves' disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism. Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy.
In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery. Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism particularly in the first trimester of pregnancy during organogenesis.
Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to methimazole for the second and third trimesters.
🧒 Pediatric Use ▾
Pediatric Use Because of postmarketing reports of severe liver injury in pediatric patient treated with propylthiouracil, methimazole is the preferred choice when an antithyroid drug is required for a pediatric patient (see DOSAGE AND ADMINISTRATION).
🆘 Overdosage ▾
OVERDOSAGE Signs and Symptoms Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.
No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or death. Treatment To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's medical status.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and tri-iodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection. Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Methimazole Tablets, USP 5 mg - white to off-white, round, flat-faced, bevelled-edged tablets, scored with "EM/5" on one side and plain on the other. They are available in: Bottles of 100 NDC 64380-212-01 Bottles of 500 NDC 64380-212-02 Methimazole Tablets, USP 10 mg - white to off-white, round, flat-faced, bevelled-edged tablets, scored with "EM/10" on one side and plain on the other. They are available in: Bottles of 100 NDC 64380-213-01 Store at controlled room temperature 15° to 30°C (59° to 86°F).
Dispense in tight, light-resistant container. Distributed by: Strides Pharma Inc. East Brunswick, NJ 08816 Revised: 12/21 OS640-01-1-16
📋 Description ▾
DESCRIPTION Methimazole (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from the drugs of the thiouracil series primarily because it has a 5- instead of a 6-membered ring. Methimazole tablet, USP contains 5 or 10 mg (43.8 or 87.6 μmol) methimazole, an orally administered antithyroid drug.
Each tablet also contains lactose monohydrate, magnesium stearate, corn starch, and talc. The molecular weight is 114.17, and the molecular formula is C 4 H 6 N 2 S. The structural formula is as follows: structural formula structural formula
💬 Information for Patients ▾
Information for Patients Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyroid drug, they should contact their physician immediately about their therapy. Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole tablets. Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis (see WARNINGS and ADVERSE REACTIONS).